Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Buys 86,432 Shares of Company Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker acquired 86,432 shares of Kodiak Sciences stock in a transaction dated Thursday, November 5th. The shares were bought at an average price of $98.51 per share, for a total transaction of $8,514,416.32. Following the transaction, the director owned 20,424,859 shares of the company’s stock, valued at approximately $2,012,052,860.09. The trade was a 0.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker bought 160,658 shares of Kodiak Sciences stock. The stock was bought at an average cost of $98.51 per share, for a total transaction of $15,826,419.58.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock. The stock was bought at an average cost of $72.57 per share, for a total transaction of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 418,323 shares of Kodiak Sciences stock. The shares were bought at an average price of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock. The shares were bought at an average price of $85.05 per share, with a total value of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 681,866 shares of Kodiak Sciences stock. The shares were bought at an average cost of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Stock Up 9.1%

NASDAQ KOD traded up $8.28 on Friday, reaching $99.30. The company had a trading volume of 1,038,739 shares, compared to its average volume of 1,128,011. The stock has a market capitalization of $6.24 billion, a PE ratio of -23.70 and a beta of 2.02. The firm’s 50 day moving average price is $68.36 and its 200 day moving average price is $43.32. Kodiak Sciences Inc. has a 12 month low of $15.83 and a 12 month high of $104.00.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, research analysts expect that Kodiak Sciences Inc. will post -3.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on KOD shares. JPMorgan Chase & Co. boosted their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. The Goldman Sachs Group initiated coverage on Kodiak Sciences in a research note on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target for the company. Weiss Ratings cut Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. HC Wainwright lifted their price objective on Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Kodiak Sciences in a research note on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Institutional Investors Weigh In On Kodiak Sciences

Hedge funds have recently bought and sold shares of the business. V Square Quantitative Management LLC bought a new position in Kodiak Sciences during the first quarter valued at $26,000. KBC Group NV purchased a new position in shares of Kodiak Sciences in the 1st quarter worth $39,000. EverSource Wealth Advisors LLC grew its stake in shares of Kodiak Sciences by 94.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after buying an additional 936 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Kodiak Sciences by 850.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock worth $124,000 after buying an additional 1,173 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in shares of Kodiak Sciences in the 1st quarter worth about $228,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.